Business Wire

GA-INSPIRE-BRANDS

17.1.2024 14:01:31 CET | Business Wire | Press release

Share
Jimmy John’s Announces Global Expansion Plan with Signing of International Franchise Agreements in Canada and Latin America

Today, Inspire Brands announced two international franchise agreements to bring Jimmy John’s, the largest owned-delivery sandwich brand in the United States, to Canada and Latin America, launching the brand’s global expansion plan.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240117651076/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Jimmy John's international store concept design (Photo: Business Wire)

Jimmy John's focus on quality ingredients, convenience and digital innovation blended with ease of operations uniquely positions the brand for international appeal. Its global expansion will usher in a new way for international guests to enjoy its iconic menu—the ability to order hot, toasted sandwiches as a customization option.

"For 40 years, Jimmy John's has taken a straightforward approach to making ridiculously good, quality sandwiches and it's now time to share them with the world," said Michael Haley, President & Managing Director, International for Inspire Brands. “In a global restaurant environment where simplicity is paramount, we're confident this brand is primed for extensive international growth."

Jimmy John’s has reached agreements with two strong operators who both possess significant quick service restaurant experience and have established extensive footprints throughout Canada and Latin America.

  • Foodtastic - A leading franchisor of restaurant brands in Canada, with more than 1,100 restaurants and $1.1 billion in sales.
  • Franquicias Internacionales - Based in El Salvador, has a robust portfolio of several complementary businesses across food and beverage, digital media and logistics.

Jimmy John’s obsessive approach to culinary excellence and operational efficiency has helped fuel its growth in the U.S. and will be the foundation of the brand’s international expansion.

Quality Obsessed:

  • Bread baked fresh in the restaurant throughout the day
  • Premium meats and cheeses, as well as fresh vegetables that are hand-sliced in restaurants daily

Convenience Obsessed:

  • Sandwiches, customized to your liking, made fresh and fast right when you want them
  • Speedy accessibility via drive-thru, pick-up, and delivery

Technology Obsessed:

  • Industry-leading mobile app and online ordering enabled through POS integration
  • Exclusive rewards through the international loyalty program

While Jimmy John's is just embarking on its global journey, Inspire Brands is no stranger to international expansion. As a multi-brand restaurant company with more than 32,000 locations worldwide, including Arby's®, Baskin-Robbins®, Buffalo Wild Wings®, Dunkin'®, Jimmy John's® and SONIC®, Inspire has a robust international presence, with more than 9,900 locations.

Jimmy John's global expansion will be supported by Inspire's extensible, shared services platform and its international team, which has a wealth of experience managing and operating brands globally.

To learn more about growth opportunities with Jimmy John’s and Inspire, please visit inspirebrands.com/franchising/international/.

About Inspire Brands

Inspire Brands is a multi-brand restaurant company whose portfolio includes more than 32,000 Arby’s, Baskin-Robbins, Buffalo Wild Wings, Dunkin’, Jimmy John’s, and SONIC locations worldwide. The company was founded in 2018 and is headquartered in Atlanta, Georgia. For more information, visit InspireBrands.com.

About Jimmy John’s

Jimmy John’s, founded in 1983, is the largest owned delivery sandwich brand in the United States, with more than 2,600 restaurants in 48 states. Jimmy John’s is part of the Inspire Brands family of restaurants. For more information, visit JimmyJohns.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240117651076/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye